

Index

Page numbers followed by “f” indicate figures; numbers followed by “t” indicate tables; “CF” indicates color figures.

- Acoustic neuroma. *See* Vestibular schwannomas
- Acquired immunodeficiency disease (AIDS)
 lymphomatous meningitis and, 376
- Acromegaly, 210
- Acroparesthesia, 398
- Acute radiation syndrome, 574–75
- Addiction and opioid analgesics, 523
- Adenocarcinoma of anterior skull base, 316
- Adenohypophysis, 208. *See also* Pituitary tumors
- Adenoid cystic carcinoma of anterior skull base, 316
- Adenoma sebaceum and tuberous sclerosis, 96
- Adenomas. *See also* Pituitary tumors
 imaging, 11, 14f
- Adjustment disorders, 578–79. *See also* Psychological issues
 prevalence, 573
- Adjuvant drugs. *See also specific medications*
 adverse effects of, 559–60
 analgesic, 517t–518t, 524–25
- Adrenal dysfunction after cancer treatment, 540
- Adrenocorticotropin (ACTH)
 after cancer treatment, 538
 measurements of, 212
 neurotrophic effects, 406–7
 paraneoplastic, 538
 and pituitary tumors, 209–10. *See also* Pituitary tumors
 treatment of, 223–25
- Advance directives, 583
- Aggression, 575
- Alpha lipoic acid and neuroprotection, 407–8
- Alpha-subunit-secreting adenomas, 219
- Altered mental status, 543–56. *See also* Psychological issues
 brain edema, 544–47, 545f
 causes, 543–44
 examination for, 544
 herniation syndromes, 549–50, 549t
 hydrocephalus, 547, 553–54
 increased intracranial pressure, 547–49, 548t
 pathophysiology, 543–44
 rehabilitation and, 473–74
 treatment, 550–54
 corticosteroids, 552–53
 hyperventilation, 551
 osmotic diuretics, 551–52
- Amenorrhea-galactorrhea syndrome, 168
- Amifostine and neuroprotection, 407
- Amputation and cancer pain, 506–7
- Amyloid neuropathy, 402
- Analgesics. *See also* Cancer pain
 adjuvant drugs, 517t–518t, 524–25
 nonopioid, 510–11, 510t
 opioid. *See* Opioid analgesics
- Anemia and behavioral changes, 560
- Aneurysms, neoplastic, 457
- Angiography, cerebral, 282–84, 283f
- Angiomas, cavernous, 20–21
- Antibodies and paraneoplastic neurologic disease, 424, 425t
- Anticonvulsants, 576. *See also* Seizure, treatment for cancer pain,
 524–25
 neurobehavioral changes, 560
- Antidepressants, 579–81, 579t
- Antiemetics
 and seizures, 441
 and syncope, 448
- Antihistamines and brain tumors, 259
- Antipsychotic medications, 575–76, 576t
- Antoni type of schwannomas, 302
- Anxiety disorder, 578
 pharmacotherapy for, 581–82, 581t
- Aphasia, 474
- Apoptosis in meningiomas, 274
- Arrhythmias and neuropathy, 399
- Arterial spin tagging (AST), 44–46
- Aseptic necrosis and chemotherapy, 508
- L-asparaginase and cerebral infarction, 464
 and hemorrhage, 457, 459–60
- Aspergillus* and cerebral infarction, 463, 465
- Astrocytes. *See also* Astrocytomas
 histology, 85, 87f
- Astrocytomas. *See also* Astrocytomas, cerebral
 cerebellar
 diffuse infiltrating, 180
 pilocytic, 177–80, 177f–179f
 malignancy and genetic alterations, 247, 247f
 optic pathway. *See* Gliomas, optic pathway
 p53-MDM2-p14^{ARF}-p21 proteins and, 245, 246f
 pineal region, 205

- Astrocytomas (*Continued*)
- spinal
 - clinical presentation, 150–52
 - epidemiology, 149–50
 - imaging, 150
 - outcome, 155
 - radiotherapy, 154
 - surgical treatment, 152–54, 153f
 - Astrocytomas, cerebral. *See also* Astrocytomas; Gliomas, cerebral
 - anaplastic
 - characteristics, 91
 - chemotherapy, 110, 110t–111t
 - in adults, 120–22, 121t
 - in children, 119–20
 - combination chemotherapy and radiotherapy, 117–19, 117t, 118t
 - radiotherapy, 112–17, 113t–115t
 - desmoplastic cerebral, 97–98
 - gemistocytic, 91
 - histologic grading, 84–85, 86–90, 87f, 88t, 89f
 - hypothalamic, 158–67. *See also* Gliomas, optic pathway
 - imaging
 - brain stem, 8, 10f
 - “butterfly” pattern, 6f, 7
 - hypothalamic, 8, 9f
 - spinal, 22, 24f
 - infiltrative
 - characteristics, 90–91
 - imaging, 4–8, 4f–7f
 - juvenile pilocytic
 - characteristics, 94–96, 96f
 - chemotherapy, 111–12
 - imaging, 7
 - radiotherapy, 110–11
 - surgical treatment, 102–3
 - low-grade
 - chemotherapy, 109–10, 110t–111t
 - radiotherapy, 105–9, 106t, 110t–111t
 - neurofibromatosis and, 25
 - outcome variables, 99
 - pleomorphic xanthoastrocytomas
 - characteristics, 97
 - surgical treatment, 103
 - subependymal giant cell
 - characteristics, 97
 - imaging, 10–11, 13f
 - surgical treatment, 102–3
 - tuberous sclerosis and, 96–97
 - Atherosclerosis and cerebral infarction, 464–65
 - Atrophy and neuropathy, 399
 - Atypical teratoid/rhabdoid tumor, 172–73
 - Autoantibodies and paraneoplastic neurologic disease, 424, 425t
 - Autonomic disorders. *See* Dysautonomia
 - Avascular necrosis and rehabilitation, 479
 - Axonal pathophysiology, 400
 - Axonal transport and neuropathy, 401
 - b*-factor value, 49
 - Back pain and spinal metastases, 342, 344t, 500–501
 - Balance abnormalities, rehabilitation of, 473
 - Balance Master System, 473
 - “Balanced analgesia,” 497
 - Barbiturates and brain tumors, 259
 - Beer and brain tumors, 255–56
 - Behavioral changes, 575. *See also* Cognitive function; Psychological issues
 - Benzodiazepines for anxiety, 581–82, 581t
 - Bereavement preparation, 583
 - Betalactams and seizures, 442
 - Bisphosphonate drugs for bone pain, 509–10
 - Bladder management, 472, 476, 482–83
 - Bleomycin and hemorrhage, 457
 - Blood–brain barrier (BBB)
 - chemotherapy and, 334–36
 - dynamic susceptibility contrast and, 42, 52f
 - Blood oxygen level dependent (BOLD) contrast, 54–55
 - Bone infiltration and cancer pain, 498–500, 509–10
 - Bourneville’s disease, 96–97
 - Bovine brain gangliosides, 406
 - Bowel management, 472, 476, 482–83
 - Brachial plexopathy, 415, 416f
 - and cancer pain, 502–3
 - rehabilitation for, 477, 477t
 - Brachytherapy, interstitial, 114–15, 115t
 - for meningiomas, 290–91
 - Brain edema and altered mental status, 544–47, 545f. *See also* Hydrocephalus; Increased intracranial pressure
 - Brain stem tumors, 171–92. *See also* Posterior fossa tumors
 - imaging, 8, 10f
 - Brain tumors. *See also* Brain tumors, metastatic; Brain tumors, primary; Pineal region tumors; Posterior fossa tumors
 - cerebral hemorrhage from, 456–57, 458f
 - treatment, 460
 - cerebral infarction from, 463–64
 - diagnosis, 466
 - treatment, 467
 - complications of, 471–74, 471t
 - etiology and epidemiology of, 252–66
 - cellular telephones, 254–55
 - drugs and medications, 259
 - electromagnetic fields, 253–54
 - food and dietary factors, 255–56
 - genetic susceptibility, 259–62
 - industry and occupation, 256–58
 - ionizing radiation, 252–53
 - viruses, 258–59
 - imaging
 - intraoperative, 78
 - metastatic, 26–27, 29, 30f–36f
 - primary, 4–22
 - single-photon emission computed tomography and, 61–65, 62f, 64f–66f
 - neurobehavioral changes with, 557–58
 - neuropsychiatric effects of, 573–75
 - primary. *See* Brain tumors, primary
 - rehabilitation for, 471–74, 471t
 - and syncope, 449
 - Brain tumors, metastatic, 321–40
 - chemotherapy, 334–36

- clinical presentation, 326, 326t
 - imaging, 26–27, 29, 30f–36f, 326
 - immunostaining, 324–25
 - incidence, 321–22
 - pathology
 - microscopic features, 323–25, 324f
 - sites, 322–23, 322f–323f
 - pathophysiology, 325–26
 - radiotherapy, 327–32
 - fractionation schemes, 328–29
 - malignant melanoma, 330
 - postoperative, 328–29
 - prophylactic, 331
 - radiation sensitizers, 328
 - radiosurgery, 329–30
 - re-irradiation, 330–31
 - renal cell carcinoma, 330
 - side effects, 331–32
 - surgical treatment, 332–34
 - treatment, 327–36
- Brain tumors, primary. *See also specific tumors***
- choroid plexus papillomas and carcinomas, 131–34, 133f
 - gliomas, 84–99. *See also Astrocytomas; Glioblastoma multiforme;*
 - Gliomas
 - pathology, 84–94
 - radiotherapy and chemotherapy, 105–28
 - stereotactic-guided volumetric resections, 77, 99
 - surgical treatment, 76–84
 - biopsy, 76–77, 99
 - frameless navigational resection devices, 77–78
 - functional mapping-guided resection, 78–84, 80f–86f
 - impact of, 99–105
 - intraoperative localization, 78, 79f
 - outcome variables, 99–105
 - reoperation, 100
 - imaging, 4–22
 - primitive neuroectodermal tumors, 128–31
 - symptoms and signs, 75–76
- BrdU**
- labeling index, 91
 - radiotherapy and, 107, 119
- Breakthrough pain, 497**
- Breast cancers**
- brachial plexopathy, 415
 - and cerebral infarction, 462, 463f
 - and hemorrhage, 457, 458f
 - and meningiomas, 272–73
 - metastatic to brain
 - histology, 323–24f
 - imaging, 35f
 - incidence, 321
 - sites, 322–23, 323f
 - metastatic to leptomeninges, 376
 - metastatic to spine
 - classification, 341, 343t
 - imaging, 30–31, 38f–39f
 - paraneoplastic neurologic disease and, 423
 - cerebellar degeneration, 430
 - dermatomyositis and polymyositis, 433
 - encephalomyelitis, 429
 - opsoclonus-myoclonus-ataxia, 431
 - post-mastectomy pain, 505–6
- Bromocriptine**
- for growth hormone-secreting adenomas, 221
 - for prolactinomas, 216
- Brown-Roberts-Wells frame, 77**
- Brown-Séquard syndrome, 344**
- Bulbar encephalomyelitis, paraneoplastic, 429**
- Bupropion for depression, 579t, 581**
- “Butterfly” pattern of astrocytomas, 6f, 7**
- Cabergoline**
- for adrenocorticotropin-secreting adenomas, 224
 - for growth hormone-secreting adenomas, 221
 - for prolactinomas, 216–17
- Calcitonin for bone pain, 510**
- Calcium channel blockers and neuroprotection, 408**
- Caloric testing, 544**
- Cancer-associated retinopathy, 431–32**
- Cancer pain, 493–535**
- analgesic adjuvant drugs, 517t–518t, 524–25
 - assessment, 495–98, 496t, 498t
 - barriers to optimal treatment, 494–95
 - increased intracranial pressure and, 550
 - knowledge deficits, 495
 - management of, 508–16
 - bone pain, 509–10
 - COX-2 enzyme inhibitors, 510t, 511
 - general principles of, 508–9
 - nonopioid analgesics, 510–11, 510t
 - opioid analgesics, 511–16, 512t. *See also Opioid analgesics*
 - routes of analgesic delivery, 516–19, 517t–518t
 - mechanisms of, 496–98, 496t
 - from metastases or trauma
 - brachial plexopathy, 502–3
 - leptomeningeal metastases, 504
 - lumbosacral plexopathy, 503–4
 - Pancoast tumors, 503
 - peripheral nerve, 501–4
 - neurosurgical and anesthetic approaches, 526–30
 - intrathecal/epidural analgesia, 528–29
 - nerve blocks, 527, 528t
 - neurosurgical procedures, 529–30, 529t
 - physical medicine approaches, 525–26
 - prevalence, 493
 - rehabilitation for, 476, 484
 - specific syndromes, 498–501, 499t
 - bone infiltration, 498–500
 - cervical spine metastasis, 500
 - lumbar spine metastasis, 500–501
 - sacral metastasis, 500–501
 - skull metastasis, 501
 - therapy related, 505–8
 - chemotherapy, 507–8
 - post-amputation, 506–7
 - post-mastectomy, 505–6
 - post-neck surgery, 506
 - post-throacotomy, 505
 - radiotherapy, 508
 - undertreatment, 493–95

- Candida* and cerebral infarction, 463
 Cannon's rule, 399
 Capsaicin for cancer pain, 525
 Carbamazepine for seizures, 446
 Carboplatin and iatrogenic neuropathy, 403t, 404
 Carcinomatous encephalopathy, 376
 Cardiac disease and syncope, 448–49
 Caregiver support for neurocognitive deficits, 567–68
 Caregiver support in rehabilitation, 567–68
 Carotid artery rupture, 464
 Cavernous angiomas, imaging, 20–21
 Cavernous sinus meningiomas, 278
CDKN2A gene, 243
 Cell cycle dysfunction and gene alterations, 245–46, 246f
 Cellular telephones and brain tumors, 254–55
 Central neurocytoma, 99
 Cerebellar pilocytic astrocytomas, 177–80, 177f–179f
 Cerebellitis, 429
 Cerebellum
 brain stem gliomas, 180–84, 181t, 183f
 ependymomas, 184–86, 184f
 pilocytic astrocytomas, 177–80, 177f–179f
 Cerebral hemorrhage, 454–60
 brain tumors, 456–57, 458f
 coagulopathy, 455–56, 456f
 diagnosis, 459
 hypertension, 458–59
 pathophysiology, 454–59, 455t
 treatment of, 460
 treatment related, 457–58
 Cerebral infarction, 460–68, 461t
 atherosclerosis, 464–65
 brain tumors, 463–64
 coagulopathy, 461–63, 462f–463f
 diagnosis, 465–67
 infection related, 463
 pathophysiology, 461–65
 treatment of, 467–68
 treatment related, 464
 Cerebral infiltrating astrocytomas. *See* Astrocytomas
 Cerebral intravascular coagulation, 462
 Cerebral lymphoma, imaging, 16, 18, 18f
 Cerebral neuroblastomas, 128–31
 Cerebral tumors. *See* Brain tumors; Brain tumors, primary
 Cerebrospinal fluid. *See also* Increased intracranial pressure and altered mental status, 547
 leptomeningeal metastases
 examination, 378–80, 379t
 flow studies, 381–83, 382t
 Cerebrovascular disease, 454–569
 cerebral hemorrhage. *See* Cerebral hemorrhage
 cerebral infarction. *See* Cerebral infarction
 and seizures, 443–44
 and syncope, 449
 Cervical plexopathy, 413–15, 414f
 Charcot-Marie-Tooth disease and neuropathy, 404
 Chemicals and brain tumors, 256–58
 Chemotherapy. *See also specific tumors*
 “8-in-1” regimen, 120
 and cancer pain, 507–8
 and cerebral hemorrhage, 457–58
 and cerebral infarction, 464
 iatrogenic neuropathy and, 403–6, 403t
 treatment, 406–8
 and neurobehavioral changes, 559
 neuropsychiatric effects of, 574
 and seizures, 440–42
 and syncope, 448–49
 Chiasmatal tumors. *See* Gliomas, optic pathway; Optic pathway tumors
 Chief cells in paragangliomas, 312
 Chlorpromazine, 576, 576t
 Chondrosarcomas of skull base, 308–10, 310f
 Chordomas
 imaging, 30, 37f
 skull base, 310–12, 311f
 Choriocarcinoma, 195. *See also* Germ cell tumors
 Choroid plexus papillomas
 and carcinomas, 131–34, 133f
 fourth ventricle, 187, 187f
 imaging, 8
 Chromophobe adenoma, imaging, 11, 14f
 Chromosomal changes
 etiology and epidemiology of brain tumors, 261–62
 in meningiomas, 274–75
 tumor suppressor genes and, 244–45
 Ciliary neurotrophic factor, 407
 Cisplatin
 and hemorrhage, 457
 and iatrogenic neuropathy, 403t, 404–6
 and seizures, 440–41
 Clonazepam, 581t, 582
 Coagulopathy
 cerebral hemorrhage from, 455–56, 456f
 diagnosis, 459
 treatment, 460
 cerebral infarction from, 461–63, 462f–463f
 diagnosis, 465
 treatment, 467
 Codeine, 513
 Cognitive function, 557–71
 changes
 diagnosis, 561–63
 due to brain tumors, 557–58
 due to treatment, 558–61
 management, 563–68. *See also* Rehabilitation
 deficit *vs.* handicap, 562
 neuropsychological assessment, 562
 and opioid analgesics, 521
 quality of life assessment, 562–63
 rehabilitation for, 473–74, 565–66, 583. *See also* Rehabilitation
 Colloid cysts, imaging, 8, 10
 Colorectal carcinoma metastatic to brain
 histology, 323–24, 24f
 incidence, 321–22
 Comparative genomic hybridization (CGH), 240, CF 9–2
 Computed tomography (CT). *See also* Diagnostic imaging
 intraoperative, 78
 meningiomas, 280
 role of, 3–4
 single-photon emission (SPECT), 62–65, 62f, 64f–66f

- spinal metastases, 346–47, 348f
- stereotactic CT-coupled frames biopsy, 77
- Contracture of joints, 479
- Contrast medium
 - blood oxygen level dependent (BOLD), 54–55
 - delayed imaging, 27
 - dynamic in magnetic resonance imaging, 46–47, 49, CF1–47
 - intraoperative tumor localization, 78
 - role of, 3–4
 - and seizures, 442
 - triple dose, 36f
- Contrast sequences and magnetization transfer, 40
- Convexity meningiomas, 278
- Cordotomy for cancer pain, 504
- Corticosteroids. *See* Steroids
- Cortisol measurements, 212–13, 212t
- COX-2 enzyme inhibitors for cancer pain, 510t, 511
- Cranial nerve tumors
 - imaging, 15–16
 - rehabilitation for, 472–73
 - schwannomas, 307–8
- Cranial neuropathy and chemotherapy, 403
- Craniopharyngiomas, 168–69
 - imaging, 14–15
- Crow-Fukase syndrome, 402
- Cryoglobulinemia and neuropathy, 402
- Cushing's disease and pituitary tumors, 211, 223–25
- Cyclosporin and seizures, 441
- Cytogenetics, 239–40. *See also* Genetics and molecular basis

- Daunorubicin and syncope, 449
- Deconditioning and rehabilitation, 480
- Deletion mapping, 240
- Delirium, 573–74
 - management of, 575–77
 - rehabilitation for, 484–85
- Dementia, 574–75
 - management of, 575–77
 - rehabilitation for, 484–85
- Depression, 577. *See also* Psychological issues
 - prevalence, 573
 - treatment, 576–77, 579–81, 579t
- Dermatomyositis, 433
- Dermoid tumors
 - imaging
 - cranial, 18, 20f–21f
 - spinal, 25
 - posterior fossa tumors, 188, 188f
- Desmoplastic cerebral astrocytomas, 97–98
- Desmoplastic infantile ganglioglioma, 98–99
- Desmoplastic medulloblastoma, 172, 173f
- Dexamethasone
 - for increased intracranial pressure, 552
 - suppression test, 224
- Diabetes insipidus. *See also* Syndrome of inappropriate antidiuretic hormone
 - after cancer treatment, 540
 - and hypothalamic gliomas, 159
 - and pituitary tumors, 210, 213
- Diabetes mellitus
 - and neuropathy, 401, 405
 - and pituitary tumors, 211
- Diagnostic imaging, 3–57
 - acoustic neuroma, 15–16, 16f
 - astrocytomas
 - brain stem, 8, 10f
 - cerebral infiltrating, 4–8, 4f–11f
 - hypothalamic, 8, 9f
 - pilocytic, 7
 - spinal, 22, 24f
 - subependymal giant cell, 10–11, 13f
 - blood vessel origin tumors, 19–21
 - brain tumors
 - etiology of, 252–53
 - metastatic, 26–27, 29, 30f–36f, 326
 - primary, 4–22
 - cavernous angiomas, 20–21
 - choroid plexus papillomas, 8
 - chromophobe adenoma, 11, 14f
 - colloid cysts, 8, 10
 - computed tomography. *See* Computed tomography (CT)
 - cranial nerve tumors, 15–16
 - craniopharyngiomas, 14–15, 168
 - dermoid tumors, 18, 20f–21f
 - developmental origin tumors
 - cranial, 18–19
 - spinal, 25
 - ependymomas, 8, 12f–13f, 22–23, 25f
 - epidermoid tumors, 18, 19f
 - epidural tumors, 29–31
 - germinomas, 15, 15f
 - glioblastoma multiforme, 4–8, 5f–10f
 - metastatic, 29
 - hemangioblastomas
 - primary cerebral, 19–20
 - spinal, 23
 - hydrocephalus, 554
 - intradural extramedullary tumors, 24–26
 - intramedullary primary tumors, 22, 24f
 - intrasellar and suprasellar tumors, 11–15
 - intraventricular tumors, 8–11
 - leptomeningeal metastases, 380–83, 380t, 382t
 - lipomas, 19, 22f
 - lymphoma, 16, 18, 18f
 - magnetic resonance imaging. *See* Magnetic resonance imaging (MRI)
 - medulloblastomas, 8, 11f
 - meningiomas, 21, 23f, 24, 279–84
 - optic nerve, 167–68
 - mesodermal origin tumors, 21, 23f
 - neurofibromatosis, 25, 28f–29f
 - oligodendrogliomas, 7
 - optic pathway gliomas, 162
 - pineal region tumors, 15
 - pineoblastoma, 15
 - pineocytoma, 15
 - pituitary tumors, 11, 213–14
 - plexopathy, 34, 43f, 420
 - positron emission tomography, 65–68

- Diagnostic imaging (*Continued*)
 posterior fossa tumors, 171
 radiation damage, 35–40, 44f–50f
 radionuclides in, 60–72. *See also* Nuclear medicine
 reticuloendothelial system tumors, 16, 18, 18f
 schwannomas, 24–25
 trigeminal, 16, 17f
 vestibular, 15–16, 16f
 scintigraphy, 62–65, 62f, 64f–66f
 single-photon emission computed tomography (SPECT), 62–65,
 62f, 64f–66f
 spinal tumors
 metastatic, 29–31, 37f–42f, 344–47, 344f–349f
 primary, 22–25, 150, 151t
 teratomas, 18
 Diazepam, 581t, 582
 “Diencephalic syndrome,” 95, 159
 Dietary factors and brain tumors, 255–56
 Diffusion imaging in magnetic resonance imaging, 49–52, 53f–54f
 Dilantin for seizures, 445–46
 Discharge planning, 486–87
 Disconnection syndromes, 574
 Disinhibition, 575
 Disseminated intravascular coagulation, 455
 treatment, 460
 Diuretics
 and brain tumors, 259
 and syncope, 448
 Docetaxel and iatrogenic neuropathy, 403t, 404
 Dorsal root ganglionitis, 430
 Down’s syndrome and brain tumors, 260
 Doxorubicin and cerebral infarction, 464
 Drug interactions and opioid analgesics, 523–24
 Drugs and brain tumors, 259
 Dynamic contrast in magnetic resonance imaging, 46–47, 49,
 CF1–47
 Dynamic susceptibility contrast (DSC), 41–42, 44, 51f–52f
 functional imaging and, 53–54
 Dysautonomia
 and neuropathy, 399–400, 404–4
 paraneoplastic neurologic disease and, 430
 rehabilitation for, 476
 Dysembryoplastic neuroepithelial tumor, 98
 Dysesthetic pain syndrome, 399
 Dysarthria, 474

 Eddy currents in magnetic resonance imaging, 52
 Edema of brain. *See* Brain edema
 EGFR gene, 242
 Electrical stimulation for cancer pain, 526
 Electrocorticography
 functional mapping-guided resection, 79
 seizure control, 101–3
 Electromagnetic fields and brain tumors, 253–54
 Electromyography and plexopathy, 420
 Embolic stroke and seizures, 443
 Embryonal cell carcinomas, 195. *See also* Germ cell tumors
 Employment
 and rehabilitation, 489
 supported, 567

 Encephalitis
 limbic, 429
 and seizures, 443
 Encephalomyelitis, paraneoplastic, 428–30, 428t
 antibodies, 426
 Encephalopathy, 573–74
 Endocarditis, nonbacterial thrombotic, 461, 462f
 Endocrine abnormalities. *See also* Neuroendocrine function
 and optic pathway gliomas, 159
 Endodermal sinus tumors, 195. *See also* Germ cell tumors
 Ependymoblastomas, cerebral, 128
 Ependymomas
 cerebral
 characteristics, 94
 chemotherapy, 127–28, 127t
 radiotherapy, 125–27, 125t
 surgical treatment, 104–5
 vs. choroid plexus carcinomas, 132
 imaging, 8, 12f–13f, 22–23, 25f
 neurofibromatosis and, 25
 posterior fossa, 184–86, 184f
 spinal
 clinical presentation, 150–52
 epidemiology, 149–50
 imaging, 150, 151t
 outcome, 155
 radiotherapy, 154
 surgical treatment, 152–54, 153f
 Epidemiology. *See also specific tumors*
 of brain tumors, 252–66
 Epidermal growth factor receptor (EGFR) gene, 242
 Epidermoid tumors
 imaging
 cranial, 18, 19f
 spinal, 25
 Epidural metastases
 leukemia and lymphoma
 clinical features, 363
 diagnosis, 363–64, 364f
 incidence, 362–66
 initial management, 364–65
 treatment, 365–66
 plexopathy and, 420
 Equipment and orthosis needs, 486
 Esthesioneuroblastomas, 314
 Estradiol measurements, 212–13, 212t
 Estramustin and syncope, 449
 Estrogen and meningiomas, 271, 292

 F-wave potential and neuropathy, 400–401
 Facial nerve schwannomas, 306
 Falx meningiomas, 278
 Familial aggregation syndromes, 260
 Family interactions and rehabilitation, 486
 Farming and brain tumors, 256–58
 Fentanyl, 515–16
 Fisch classification, 313t
 Fluid attenuated inversion recovery (FLAIR), 40
 Fluorescence in situ hybridization (FISH), 239–40, CF 9–1

- 5-Fluorouracil
and seizures, 441
and syncope, 448
- Follicle-stimulating hormone
measurements of, 212–13, 212t
and pituitary tumors, 210–11. *See also* Pituitary tumors
treatment, 219–21
- Food and brain tumors, 255–56
- Foramen magnum meningiomas, 279
- Formaldehyde and brain tumors, 258
- Fourth ventricle
choroid plexus papillomas, 187, 187f
dermoid tumors, 188, 188f
subependymomas, 186–87, 186f
- Frameless navigational resection devices, 77–78
- Frontal lobe
brain tumor symptoms and, 76
herniation syndromes, 550
- Functional Independence Measure, 488f, 489
- Functional magnetic resonance imaging (fMRI), 52–55
- Functional mapping-guided resection, 78–84, 80f–86f
- Furosemide and increased intracranial pressure, 552
- Gabapentin, 406
for cancer pain, 525
for seizures, 447
- Gabitril for seizures, 447
- Galactorrhea and pituitary tumors, 211
- Gangliogliomas, cerebral
characteristics, 98
desmoplastic infantile, 98–99
surgical treatment, 105
- Gangliogliomas, spinal, 149
- Gastrointestinal symptoms of brain tumor, 75
- Gemistocytes, 85, 91
- Gene therapy for leptomeningeal metastases, 390
- Genetic and molecular basis of brain tumors, 239–51
cell cycle dysfunction, 245–46, 246f
chromosomal regions, 244–45
classification of cancer genes, 241–45, 241t
comparative genomic hybridization (CGH), 240, CF 9–2
etiology and epidemiology, 259–62
fluorescence in situ hybridization (FISH), 239–40, CF 9–1
future research, 247–48
gene alterations, 245–46, 246f
high-grade malignancy and, 247, 247f
linkage analysis, 240
loss of heterozygosity (LOH) analysis, 240–41
methods, 239–41
oncogenes, 242
therapeutic implications, 248
tumor suppressor genes (TSGs), 242–44
- Germ cell tumors
imaging, 15, 15f
metastatic, 29, 33f
pineal region, 193–203
biopsy, 200
chemotherapy, 202–3
clinical presentation, 196, 197f–198f
epidemiology, 193–95
general management, 196, 198–99
pathology, 193–96, 194t–195t, 195f
radiotherapy, 201–2
recurrence management, 203
surgical treatment, 199–201
tumor markers, 195t, 196
- Germinomas. *See* Germ cell tumors
- Glial fibrillary acidic protein (GFAP), 128
- Glioblastoma multiforme
characteristics, 91–92
chemotherapy, 110, 110t–111t
in adults, 120–22, 121t
in children, 119–20
combination chemotherapy and radiotherapy, 117–19, 117t, 118t
EGFR gene and, 242
histologic grading, 87–88
imaging, 4–8, 4f–7f, 29
optic pathway, 158
radiotherapy, 112–17, 113t–115t
vs. anaplastic astrocytomas, 92
- Gliomas
brain stem, 180–84, 181t, 183f
cerebral. *See also* Glioblastoma multiforme; *specific types*
astrocytomas. *See* Astrocytomas
central neurocytoma. *See* Central neurocytomas
desmoplastic infantile ganglioglioma, 98–99
dysembryoplastic neuroepithelial tumor, 98
ependymomas, 94
surgical treatment, 103–5
ganglioglioma, 98
glioblastomas, 91–92
gliosarcomas, 92
histologic grading, 84–85, 86–90, 87f, 88t, 89f
infiltrative
characteristics, 90–94
general features, 84–88, 87f
grading systems, 88–90, 88t
pathology of, 84–94
radiotherapy for, 105–10, 106t
surgical treatment, 100–103
juvenile pilocytic astrocytomas. *See* Astrocytomas
mixed neuronal-glial tumors, 98–99
noninfiltrative
characteristics, 94–99
pathology, 94–99
surgical treatment, 102–3
oligoastrocytomas, 93–94
oligodendroglial tumors, 92–93, 93f
outcome variables, 99–103
pleomorphic xanthoastrocytomas. *See* Astrocytomas
radiotherapy and chemotherapy, 105–10, 106t, 110t–111t
subependymal giant cell. *See* Astrocytomas
surgical treatment, 100–105
tuberous sclerosis, 96–97
optic pathway, 158–70
chemotherapy, 165–66
clinical presentation, 159–60, 160t
complications, 166–67
diagnosis, 162

- Gliomas** (*Continued*)
- imaging, 8, 9f
 - management, 162–66
 - pathology, 158–59
 - prognosis, 160–61, 161t
 - radiosurgery, 164–65
 - radiotherapy, 164–65
 - surgical treatment, 162–64
 - seizures and, 438
- Gliosarcomas, cerebral**
- characteristics, 92
 - surgical treatment, 104
- Glomus jugulare tumors, 312, 313t**
- Glomus tympanicum tumors, 312**
- Glomus vagale tumors, 312**
- Glucocorticoids in cancer treatment, 538**
- Glutathione and neuroprotection, 407**
- Glycerol for increased intracranial pressure, 552**
- Gonadotropin-secreting adenomas, 219–21**
- Gradient subsystem changes in magnetic resonance imaging, 40–41**
- Grading of tumors. *See names of specific tumors and grading schemes***
- Granulomatous angiitis and cerebral infarction, 465, 468**
- Growth hormone**
- after cancer treatment, 539
 - and hypothalamic gliomas, 159
 - measurements of, 212–13, 212t
 - and pituitary tumors, 209–10. *See also* Pituitary tumors
 - treatment of, 221–23
- Haloperidol, 575–76, 576t**
- for anxiety, 581t, 582
- “Head Start 1” chemotherapy regimen, 131**
- Headache**
- brain tumor symptoms, 75
 - leptomeningeal metastases, 376
 - pituitary tumors, 211–12
- Heart failure and syncope, 449**
- Hemangioblastomas**
- cerebral, imaging, 19–20
 - spinal
 - clinical presentation, 150–52
 - epidemiology, 149–50
 - imaging, 23, 150
 - outcome, 155
 - radiotherapy, 154
 - surgical treatment, 152–54
 - tumor suppressor genes and, 244
- Hemangiopericytoma, 276, 277f**
- Hemolytic uremic-like syndrome, 457, 459**
- Hemorrhage**
- cerebral. *See* Cerebral hemorrhage
 - and seizures, 444
- Hereditary syndromes and brain tumors, 260–61. *See also* Genetic and molecular basis of brain tumors**
- Herniation**
- cerebral
 - altered mental status and, 549–50, 549t
 - imaging, 5, 5f
 - metastatic brain tumors, 326
 - of disc, imaging, 34, 35f
- Herpes virus and brain tumors, 259**
- Hodgkin’s disease. *See* Lymphoma**
- Homer-Wright fibrillary rosettes, 128**
- Hormones**
- and meningioma
 - chemotherapy, 291–92
 - etiology, 271–72, 271t
 - neuroendocrine function and. *See* Neuroendocrine function; *specific hormones*
- Horner’s syndrome, 415**
- “Hot dry foot,” 418**
- Human Genome Project, 247–48**
- Hyams’ grading system, 314t**
- Hydrocephalus**
- altered mental status and, 547, 553–54
 - germ cell tumors, 199–200
 - imaging, 554
 - juvenile pilocytic astrocytomas, 95
 - leptomeningeal metastases, 376
 - rehabilitation and, 472
 - subependymal giant cell astrocytomas, 96–97
- Hydrocodone, 513**
- Hydromorphone, 514**
- Hypercalcemia, 536–37**
- Hypercortisolism, 538**
- Hyperfractionated radiotherapy, 114**
- Hyperleukocytosis and hemorrhage, 457**
- Hyperpathia, 398**
- Hyperprolactinemia after cancer treatment, 540**
- Hypertension and cerebral hemorrhage, 458–59**
- Hyperthermia and increased intracranial pressure, 548**
- Hyperthyroidism and pituitary tumors, 211**
- Hyperventilation for altered mental status, 551**
- Hypocalcemia and seizures, 443**
- Hypoglycemia**
- after cancer treatment, 537–38
 - and seizures, 443
 - and syncope, 448
- Hypogonadism after cancer treatment, 539–40**
- Hypomagnesemia**
- and iatrogenic neuropathy, 405
 - and seizures, 443
- Hyponatremia, 537**
- increased intracranial pressure and, 551
 - and seizures, 442
- Hypophysectomy for bone pain, 510**
- Hypopituitarism. *See also* Neuroendocrine function; Pituitary tumors**
- craniopharyngiomas and, 168
 - optic pathway gliomas and, 164
- Hypotension**
- increased intracranial pressure and, 551
 - orthostatic
 - and neuropathy, 399
 - rehabilitation for, 480
 - and syncope, 447–48
- Hypothalamic dysfunction after cancer treatment, 537t, 538–41**
- Hypothalamic obesity after cancer treatment, 540–41**
- Hypothalamic tumors, 158–70. *See also* Gliomas, optic pathway; Optic pathway tumors**
- Hypothermia and increased intracranial pressure, 548**

- Hypoxia
and radiotherapy, 119
and seizures, 443
- Ifosfamide and seizures, 441
- Imaging. *See also specific tumors*
diagnostic. *See* Computed tomography (CT); Diagnostic imaging;
Magnetic resonance imaging (MRI)
intraoperative, 78
- Imipenem/cilastatin and seizures, 442
- Immunotherapy
for leptomeningeal metastases, 389–90
for meningiomas, 291
neurobehavioral changes and, 559
- In vivo spectroscopy, 55–57, 56f
- “Incidentalomas,” 220
- Increased intracranial pressure. *See also* Hydrocephalus
altered mental status, 547–49, 548t
headache and, 75
leptomeningeal metastases, 376
meningiomas, 273
metastatic brain tumors, 326
neuropsychiatric effects of, 574
posterior fossa tumors, 172
- Indomethacin for increased intracranial pressure, 552
- Industry and brain tumors, 256–58
- Infarction, cerebral. *See* Cerebral infarction
- Infection
and cerebral infarction, 463
and seizures, 443
- Influenza virus and brain tumors, 259
- Insulinoma
and seizures, 443
and syncope, 448
- Interferon and seizures, 441
- Interstitial brachytherapy. *See* Brachytherapy, interstitial
- Intradural extramedullary tumors, imaging, 24–26
- Intramedullary spinal tumors
imaging
metastatic, 24, 26f–27f
primary, 22, 24f
- Intrasellar tumors, imaging, 11–15
- Intrathecal/epidural analgesia, 528–29
- Intraventricular meningiomas, 278–79
- Ionizing radiation and brain tumors, 252–53
- Iproplatin and iatrogenic neuropathy, 403t, 404
- Isaxonine, 406
- Isoniazid and iatrogenic neuropathy, 404
- Jefferson’s type of schwannomas, 304
- Joint contractures and rehabilitation, 479
- Jugular foramen schwannomas, 306–7, 307f
- Jugular foramen syndrome, 301t
- Juvenile pilocytic astrocytomas. *See* Astrocytomas
- Karnofsky Performance Scale, 487–89, 487t
- Karnofsky performance status (KPS), 107
- Kernohan’s notch phenomenon, 549
- Ketamine for cancer pain, 525
- Ki-67 antigen labeling, 91
- Kyphoscoliosis, 154
- Lambert-Eaton myasthenic syndrome, 432–33
antibodies, 426
- Lamictal for seizures, 447
- Lamotrigine for seizures, 447
- Landry-Guillain-Barré-Strohl syndrome, 400, 404
- Language function tests, 79–84, 84f–86f
- Lanreotide for thyroid-stimulating hormone adenomas, 226
- Laser vaporization, stereotactic, 77
- Leptomeningeal metastases, 375–93
and cancer pain, 504
chemotherapy
intrathecal, 385–87, 386f
new approaches, 387–90, 389t
systemic, 384–85
clinical presentation, 376–78, 376t–377t
diagnosis, 378–83
cerebrospinal fluid examination, 378–80, 379t
imaging, 380–83, 380t, 382t
imaging, 29, 34f, 368f
incidence, 375–76
leukemia and lymphoma, 376
chemotherapy, 370–71, 370t
clinical features, 366–67, 367t
diagnosis, 367–69, 368f
incidence, 366, 366t
initial management, 369
neurotoxicity, 372
outcome, 371–72
radiotherapy, 369
pathology, 322–23, 322f
plexopathy and, 420
radiotherapy, 383–84
rehabilitation for, 478
treatment, 383–90
- Leukemia
coagulopathy and, 455
and hemorrhage, 459
and lymphoma metastases, 362–74
epidural, 362–66. *See also* Epidural metastases
leptomeningeal, 366–72. *See also* Leptomeningeal metastases
- Levorphanol, 514–15
- Lhermitte’s sign, 405
- Li-Fraumeni syndrome, 260–61
- Lidocaine for cancer pain, 525
- Limb postures, 544
- Limbic encephalomyelitis, paraneoplastic, 429
- Limited-field radiotherapy, 112–14
- Linkage analysis, 240
- Lipomas, imaging, 19, 22f
- Lithium for depression, 579t, 581
- Lorazepam, 581t, 582
- Loss of heterozygosity (LOH) analysis, 240–41
- Lumbosacral plexopathy, 416–18, 417f
and cancer pain, 503–4
rehabilitation for, 477–78, 477t
- Lung cancers
brachial plexopathy, 415
and cerebral infarction, 464
metastatic to brain
hemorrhage and, 456

- Lung cancer (*Continued*)
 imaging, 32f
 incidence, 321
 site, 323–24, 323f
 metastatic to spine
 classification, 341, 343t
 paraneoplastic neurologic disease and, 423
 dermatomyositis and polymyositis, 433
 encephalomyelitis, 429
 Lambert-Eaton myasthenic syndrome, 432
 opsoclonus-myoclonus-ataxia, 431
 sensory neuronopathy, 430
- Luteinizing hormone
 measurements of, 212–13, 212t
 and pituitary tumors, 209–10. *See also* Pituitary tumors
 treatment, 219–21
- Lymphedema and plexopathy, 419, 419t
- Lymphomas
 brachial plexopathy, 415, 416f
 and hemorrhage, 459
 imaging
 cerebral, 16, 18, 18f
 spinal, 31, 42f
 metastatic. *See* Leukemia and lymphoma metastases
 paraneoplastic neurologic disease and
 cerebellar degeneration, 430
 encephalomyelitis, 429
 subacute motor neuronopathy and, 432
 and seizures, 442
- Macroadenomas. *See* Pituitary tumors
- Mafosfamide, 388
- Magnetic resonance imaging (MRI)
 acquisition rates in magnetic resonance imaging, 40–41
 advanced techniques, 40–57
 contraindications to, 4
 diffusion imaging, 49–52, 53f–54f
 dynamic contrast, 46–47, 49, CF1–47
 functional, 52–55
 functional mapping-guided resection, 80–84, 80f–81f, 83f–84f
 intraoperative, 78
 meningiomas, 280–82, 281f
 perfusion imaging pulse sequences, 41–46, 51f–52f
 radiation damage and, 37–40, 44f–50f
 role of, 3–4
 “shine-through,” 50
 spinal tumors
 metastatic, 347, 349f
 primary, 150, 151t
 in vivo spectroscopy, 55–57, 56f
- Magnetization transfer contrast sequences, 40
- Malignant melanoma
 lumbosacral plexopathy, 417, 417f
 metastatic to brain
 hemorrhage and, 456
 imaging, 34, 43f
 incidence, 321
 sites, 322, 322f
 metastatic to leptomeninges, 376
- Mannitol for increased intracranial pressure, 551
- Mapping-guided resection, 78–84, 80f–86f
- Massage therapy for cancer pain, 526
- Mastectomy and cancer pain, 505–6
- Medroxyprogesterone and meningiomas, 272, 292
- Medulloblastomas, 172–77, 173f
 in adults, 177
 chemotherapy, 175–77
 imaging
 metastatic, 34f
 primary, 8, 11f
 presentation, 173–74
 radiotherapy, 175
 staging, 174, 174t
 surgical treatment, 174–75
 tumor suppressor genes and, 244
- Medullomyoblastoma, 172
- Melanocyte-stimulating hormone, neurotrophic effects, 406–7
- Melanoma. *See* Malignant melanoma
- Meningeal gliomatosis. *See* Leptomeningeal metastases
- Meningeal hemangiopericytoma, 276, 277f
- Meningiomas, 269–99
 angiogenesis, 273–74
 apoptosis, 274
 clinical presentation, 277–79
 etiology, 270–73, 271t
 genetics, 274–76
 history, 269
 imaging, 21, 23f, 24, 167–68, 279–84
 cerebral angiography, 282–84, 283f
 computed tomography, 280
 magnetic resonance imaging, 280–82, 281f
 plain radiographs, 279–80
 incidence, 269–70
 location, 270
 malignant, 292–93, 292t
 medroxyprogesterone, 272, 292
 optic nerve, 167–68
 pathology, 276–77, 276f–277f
 skull base, 300, 302
 treatment, 284–92
 chemotherapy, 291–92
 observation, 284
 preoperative embolization, 282–84, 283f
 radiotherapy, 287–91, 288t–289t
 surgical treatment, 284–87, 285t, 286f
- Meningitis
 neoplastic. *See* Leptomeningeal metastases
 and seizures, 443
- Meperidine, 513
 and seizures, 441
- Merlin and meningiomas, 275
- Mesenchymal chondrosarcomas, 309
- Mesodermal origin tumors, imaging, 21, 23f
- Metabolic susceptibility to brain tumors, 261
- “Metabolite maps,” 55, CF1–53, CF1–54
- Metastasis(es). *See also specific tumors and locations*
 brain. *See* Brain tumors, metastatic
 glioblastoma multiforme and, 7, 7f, 29
 intracranial, 321–40
 leukemia and lymphoma, 362–74
 spinal. *See* Spinal tumors, metastatic
- Methadone, 515

- Methotrexate and seizures, 440
- Methylphenidate, 576–77, 579t, 580
and seizures, 442
for neurocognitive deficit, 567, 567t
- MIB-1 labeling index, 91
- Microadenomas. *See* Pituitary tumors
- Microarrays and genes, 247–48
- Microwave hyperthermia, 115
- Mifepristone and meningiomas, 272, 292
- Mirtazepine for depression, 579t, 580
- Mitoxantrone and syncope, 449
- Mixed neuronal-glioma tumors, 98–99
- Molecular genetics, 240–41. *See also* Genetics and molecular basis
- Monoamine oxidase inhibitors (MAOIs), 579t, 581
- Monoclonal antibodies for leptomeningeal metastases, 389
- Monoclonal gammopathy of uncertain significance syndrome and peripheral neuropathy, 402
- Mononeuritis multiplex and cryoglobulinemia, 402
- Morphine, 514
and seizures, 441
- Motor evoked potential (MEP) in spinal surgery, 152
- Motor mapping, 79–81, 80f–83f
- Motor neuropathy, 399
and cisplatin, 405
and paraproteinemias, 402–3
- Moyamoya and radiotherapy, 167
- MR spectroscopy (MRS), 55–57, 56f
- Multiple melanoma metastasis, imaging, 30f, 32f–33f
- Multiple myeloma, metastatic, 31
- Musculoskeletal rehabilitation, 478–80
- Mutagen sensitivity and brain tumors, 261
- Myelin pathophysiology, 400–401
- Myelitis and paraneoplastic neurologic disease, 429
- Myelography
role of, 3–4
spinal metastases, 344, 347f
- Myelopathies and rehabilitation, 474–75, 475t
- Myopathy, corticosteroid-induced, 478–79
- Naming tests, 79–84, 84f–86f
- Narcotics. *See also* Opioid analgesics
for neuropathy, 406
and seizures, 441
- Nasal cavity schwannomas, 308
- Neck pain and spinal metastases, 342, 344t
- Neck surgery and cancer pain, 506
- Necrosis
grading classification, 88–89, 89t
glioblastoma *vs.* anaplastic astrocytomas, 92
radiation-induced, 37–40, 44f–50f
- Nefazodone for depression, 579t, 580
- Nelson's syndrome, 225, 229
- Neoplastic meningitis. *See* Leptomeningeal metastases
- Nerve blocks for cancer pain, 527, 528t
- Nerve growth factor, 407
- Neurinomas. *See* Schwannomas
- Neuroblastomas, olfactory, 314–16, 314t, 315f
- Neurocognitive function, 557–71. *See also* Cognitive function
- Neurocytomas
central
characteristics, 99
vs. primitive neuroectodermal tumors, 128
spinal, 149
- Neuroendocrine carcinomas of anterior skull base, 316
- Neuroendocrine function, 536–42
behavioral changes and, 560
effects of systemic therapy, 536–38
following treatment, 537t, 538–41
hypercalcemia, 536–37
hypercortisolism, 538
hypoglycemia, 537–38
hyponatremia, 537
surveillance after treatment, 537t, 541
- Neuroepithelial tumor, dysembryoplastic, 98
- Neurofibromatosis
imaging, 25, 28f–29f
optic pathway gliomas and, 159–60, 162
and schwannomas, 302
skull base, 308
tumor suppressor genes and, 244
- Neurofibromin and meningiomas, 275
- Neurofibrosarcoma and neurofibromatosis, 25
- Neuronal-glioma tumors, mixed, 98–99
- Neurontin for seizures, 447
- Neuropathy(ies), peripheral. *See* Peripheral neuropathy(ies)
- Neuroprotective drugs, 406–8
- Neurosurgical procedures for cancer pain, 529–30, 529t
- Nevoid basal cell carcinoma syndrome and tumor suppressor genes, 244
- NF1* gene, 244, 275
- NF2* gene, 244, 275
- Nimodipine and neuroprotection, 408
- Nitrosation and brain tumor etiology, 255
- Non-Hodgkin's lymphoma. *See also* Leukemia and lymphoma
metastases; Lymphomas
metastases, 362–74
- Nonbacterial thrombotic endocarditis and cerebral infarction, 461, 462f
- Nongerminomatous germ cell tumors (NGGCT). *See* Germ cell tumors
- Nonopioid analgesics for cancer pain, 510–11, 510t
- Nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain, 509–11, 510t
- Nuclear medicine, 60–72. *See also* Diagnostic imaging
for bone pain, 509
cerebrospinal fluid flow studies, 381–83, 382t
positron emission tomography, 65–68
radionuclide therapy, 68–69
scintigraphy, 62–65, 62f, 64f–66f
in vitro vs. in vivo studies, 60–61
- Null cell adenomas, 209. *See also* Pituitary tumors
- Nutrition and rehabilitation, 483–84
- Occupation and brain tumors, 256–58
- Octreotide
for growth hormone-secreting adenomas, 221
for pituitary tumors, 219
for thyroid-stimulating hormone adenomas, 226
- Oculocephalic reflex, 544
- Olanzapine, 576, 576t
- Olfactory groove meningiomas, 277–78
- Olfactory neuroblastomas, 314–16, 314t, 315f

- Oligoastrocytomas, cerebral
 characteristics, 93–94
 chemotherapy, 124t, 125
 radiotherapy, 122–24, 123t
- Oligodendrogliomas, cerebral, 7
 characteristics, 92–93, 93f
 chemotherapy, 124–25, 124t
 grading schemes, 90
 radiotherapy, 122–24, 123t
- Oncogenes
 etiology and epidemiology of brain tumors, 242
 in meningiomas, 275–76
- Opioid analgesics, 511–16, 512t
 complications of, 522–24
 depression and, 577
 equianalgesic dosing, 519, 520t
 guidelines for use, 519–22, 520t
 side effects, 520–21
 “strong,” 514–16
 “weak,” 512–14
- Opsoclonus-myoclonus-ataxia, paraneoplastic, 431
- Optic neuropathy and platinum, 408
- Optic pathway tumors
 craniopharyngiomas, 168–69
 gliomas. *See* Gliomas, optic pathway
 meningiomas, 167–68
 pituitary tumors, 211
- Organic mental syndromes, prevalence, 573
- Ormaplatin and iatrogenic neuropathy, 403t, 404
- Orthostatic hypotension. *See* Hypotension
- Orthotic needs, 472, 486
- Osmotic diuretics for altered mental status, 551–52
- Ossification, heterotopic, 479–80
- Osteoporosis and rehabilitation, 479
- Osteosarcoma metastatic to brain, 324, 324f
- Ototoxicity
 and cisplatin, 405
 and platinum, 408
- Oxycodone, 513–14
- p16-cdk4-pRb-cyclin D proteins, 245–46, 246f
- p53-MDM2-p14^{ARF}-p21 proteins, 245, 246f
- Paclitaxel
 and iatrogenic neuropathy, 403–4, 403t
 and seizures, 441
- Pain. *See* Cancer pain
- Pancoast tumors and cancer pain, 503
- Panic attacks, 578
- Papillary meningiomas, 276, 277f
- Paragangliomas of skull base, 312–14, 313f, 313t
- Parametric maps in magnetic resonance imaging, 49, CF1–47
- Paranasal sinus schwannomas, 308
- Paraneoplastic cerebellar degeneration, 430–31
 antibodies, 426
- Paraneoplastic neurologic disease (PND), 423–37
 antibody clinical uses, 425t, 426
 cerebellitis, 429
 classification, 426–28, 427t
 dermatomyositis, 433
 dysautonomia, 430
 encephalomyelitis, 428–30, 428t
 historic considerations, 424, 425t
 incidence, 423–24
 Lambert-Eaton myasthenic syndrome, 432–33
 myelitis, 429
 paraneoplastic cerebellar degeneration, 430–31
 paraneoplastic opsoclonus-myoclonus-ataxia, 431
 and paraproteinemias, 403
 pathogenesis, 424, 426
 polymyositis, 433
 retinal degeneration, 431–32
 seizures and, 440
 subacute motor neuronopathy, 432
 subacute sensory neuronopathy, 430
 tumors associated with, 427–28, 427t
- Paraneoplastic opsoclonus-myoclonus-ataxia, 431
 antibodies, 426
- Paraproteinemias
 paraneoplastic syndromes and, 403
 peripheral neuropathy and, 401–3, 402t
- Parasagittal meningiomas, 278
- Parinaud’s syndrome, 181
- Parkinsonism and rehabilitation, 485
- Patient outcome goals for rehabilitation, 487–89, 487t, 488f
- Pegvisomant, 221
- Perfusion imaging pulse sequences, 41–46, 51f–52f
- Perineal pain syndrome, 501
- Peripheral neuropathy(ies), 397–412. *See also* Paraneoplastic neurologic disease (PND)
 and cancer pain, 501–4, 508
 clinical features, 398–400
 demyelinating, 400–401
 iatrogenic, 403–6, 403t
 treatment, 406–8
 incidence, 397
 morbidity, 397–98
 motor nerve symptoms, 399
 paraproteinemias and, 401–3, 402t
 pathophysiology, 400–401
 rehabilitation for, 478
 sensory nerve symptoms, 398–99, 398t
 small fiber nerves, 399–400
- Personality changes, 575. *See also* Psychological issues
- Pesticides and brain tumors, 257
- Petroclival meningiomas, 279
- Phantom limb, 506–7
- Phenobarbital for seizures, 446–447
- Phenytoin
 adverse effects of, 560
 for cancer pain, 525
 depression and, 577
 for seizures, 445–46
- Physical medicine approaches for cancer pain, 525–26
- Pilocytes, 95
- Pilocytic astrocytomas. *See* Astrocytomas
- Pineal region tumors, 193–207
 astrocytomas, 205
 biopsy, 200
 germ cell tumors, 193–203, 194t–195t, 195f. *See also* Germ cell tumors

- imaging, 15
- pineocytomas/pineoblastomas, 203–5, 203f–204f
- surgical approaches, 200–201
- Pineoblastomas, 128–31, 203–5, 203f–204f
 - imaging, 15
- Pineocytomas, 203–5, 203f–204f
 - imaging, 15
- Pituitary dysfunction after cancer treatment, 537t, 538–41. *See also* Neuroendocrine function
- Pituitary tumors, 208–36. *See also* Neuroendocrine function
 - apoplexy and, 230
 - classification of, 209
 - clinical presentation, 210–12
 - depression and, 577
 - gonadotropin-secreting adenomas, 219–21
 - imaging, 11, 14f, 213–14
 - laboratory investigations, 212–13, 212t
 - malignant, 226–30, 227f–228f
 - natural history, 210
 - pathology, 208–10, 209f
 - prolactinomas, 216–19
 - skull base, 302
 - specific types, 216–26, 216t
 - adrenocorticotropic-secreting adenomas, 223–25
 - clinically nonfunctional adenomas, 219–21
 - growth hormone-secreting adenomas, 221–23
 - thyroid-stimulating hormone secreting adenomas, 225–26
 - surgical approaches, 214–15
 - treatment, 214–15
- Plasmacytoma and neuropathy, 402
- Platinum and iatrogenic neuropathy, 403–6, 403t
- Pleomorphic xanthoastrocytomas
 - characteristics, 97
 - surgical treatment, 103
- Plexopathy(ies), 413–22
 - brachial, 415, 416f
 - cervical, 413–15, 414f
 - chemotherapy and, 419
 - diagnosis, 420
 - differential diagnosis, 418–20, 419t
 - imaging, 34, 43f
 - lumbosacral, 416–18, 417f
 - prevalence, 413
 - radiation *vs.* tumor, 418–20, 419t
 - rehabilitation for, 476–78, 477t
 - treatment, 420–21
- PNET. *See* Primitive neuroectodermal tumors (PNET)
- POEMS syndrome, 402
- Poliovirus vaccination and brain tumors, 258–59
- Polycythemia vera and cerebral infarction, 465
- Polymorphisms, 240
 - etiology and epidemiology of brain tumors, 261
- Polymyositis, 433
 - antibodies, 426
- Polyvinyl chloride and brain tumors, 258
- Positron emission tomography (PET), 65–68
 - radiation damage imaging, 36
- Post-herpetic neuralgia, 508
- Posterior fossa
 - herniation syndromes, 549–50
 - tumors, 171–92
 - brain stem gliomas, 180–84, 181t, 183f
 - cerebellar diffuse infiltrating astrocytomas, 180
 - cerebellar pilocytic astrocytomas, 177–80, 177f–179f
 - choroid plexus papillomas, 187, 187f
 - dermoid tumors, 188, 188f
 - ependymomas, 184–86, 184f
 - medulloblastoma, 172–77, 173f, 174t
 - meningiomas, 279
 - subependymomas, 186–87, 186f
- Precocious puberty and hypothalamic gliomas, 159
- Pregnancy
 - diagnostic imaging and, 4
 - and meningiomas, 272
- Pressure ulcers, 482, 482t
- Primary cerebral tumors. *See* Brain tumors, primary
- Primitive neuroectodermal tumors (PNET)
 - “Head Start 1” chemotherapy regimen, 131
 - cerebral, 128–31
 - spinal, 149
- Progesterone and meningiomas, 271–72, 271t
- Prolactin
 - after cancer treatment, 540
 - measurements of, 212–13, 212t
 - and pituitary tumors, 209–10. *See also* Pituitary tumors; Prolactinoma
- Prolactinomas, 14f, 209f
 - treatment of, 216–19
- Propoxyphene, 513
 - and seizures, 441
- Prostate carcinoma
 - metastatic to brain, 323–23
 - metastatic to spine
 - classification, 341, 343t
 - imaging, 30–31, 40f–40f
- Proton density-weighted (PDW) acquisitions, 40
- Protons and helium ion beams in radiotherapy, 116–17
- Protooncogenes in meningiomas, 275–76
- Pseudodementia, 575
- Pseudorheumatism, steroid, 508
- Psychiatric issues. *See* Psychological issues
- Psychological intervention for cancer pain, 526
- Psychological issues, 572–89. *See also* Altered Mental Status; *specific disorders*
 - adjustment disorder, 578–79
 - anxiety disorder, 578
 - assessment of cognitive function, 562
 - for cancer survivors, 587
 - delirium, 573–74
 - dementia, 574–75
 - depression, 577
 - for families, 584–86
 - for medical staff, 586–87
 - mood and anxiety disorders, 577–82
 - prevalence, 572–73
 - psychotherapy for, 582–87
 - and rehabilitation, 485–86
 - relaxation therapy, 583
 - for spouses, 584–86
- Psychosocial issues. *See* Psychological issues

- Psychostimulants, 576–77, 579t, 580
 Psychotherapy, 582–87
PTCH gene, 244
P TEN/MMAC1 gene, 243
 Pupillary light reaction, 544
- Quality of life
 - assessment, 562–63
 - behavioral changes and, 560–61
 - and rehabilitation, 489, 489t
- Quinagolide for prolactinomas, 216
 Quinolones and seizures, 442
- Radiation damage. *See also* Radiotherapy
 - basis for, 35–36
 - brain tumor etiology and, 252–53, 261
 - imaging, 35–40
 - brain, 37–40, 44f–50f
 - moyamoya, 167
 - myelopathies, 475, 475t
 - neurobehavioral changes and, 558–59
 - plexopathy, 418–20, 419t
- Radiosurgery. *See also* Radiotherapy
 - brain tumors, primary, 77, 116
 - for meningiomas, 289–90, 289t
 - optic pathway gliomas, 164–65
 - for prolactinomas, 218
- Radiotherapy. *See also* Nuclear medicine; Radiation damage; *specific tumors*
 - accelerated fractionation radiotherapy, 114
 - brain tumor etiology and, 252–53
 - and cancer pain, 508
 - cerebral hemorrhage, 457–58
 - cerebral infarction, 464
 - dose-escalation radiotherapy, 114
 - hyperfractionated radiotherapy, 114
 - neuropsychiatric effects of, 574
 - seizures and, 440
 - skin and wound care after, 481–82
 - stereotactic, 165
 - stroke and, 443
- ras pathway and meningiomas, 274
 Rathke's pouch and craniopharyngioma, 14, 168
 Recombinant DNA, neurotrophic, 407
 Recoverin, 432
 Reflex sympathetic dystrophy, 497
 Regional cerebral blood flow (rCBF), 41, 51f
 Regional cerebral blood volume (rCBV), 41, 51f
 Rehabilitation, 470–92
 - balance abnormalities, 473
 - benefits, 471, 471t
 - bowel and bladder management, 472, 482–83
 - for brain tumors, 471–74, 471t
 - cognitive, 473–74, 565–66
 - cranial nerve deficits, 472–73
 - deconditioning and, 480
 - delirium and dementia, 484–85
 - discharge planning, 486–87
 - employment, 489
 - equipment and orthosis needs, 486
- family interactions, 486
 inpatient programs, 565
 leptomeningeal metastases, 478
 musculoskeletal, 478–80
 neuropathy, 478
 nutrition, 483–84
 pain, 484
 parkinsonism, 485
 patient outcome goals, 487–89, 487t, 488f
 pharmacologic strategies, 567, 567t
 plexopathy, 476–78, 477t
 problems with, 563–64
 psychological issues, 485–86
 purpose of, 470–71, 471t
 quality of life, 489, 489t. *See also* Quality of life
 sexual dysfunction, 486
 skin and wound care, 481–82, 482t
 spasticity, 480–81, 481t
 speech deficits, 473–74, 583
 spinal cord tumors, 474–76, 475t
 traditional approaches, 564–65
 venous thromboembolism, 480
 vocational, 566–67
- Relaxation therapy, 583
 Renal cell carcinoma metastatic to brain, 321–22
 Respiratory depression and opioid analgesics, 521–22
 Restless leg syndrome, 398
 Reticuloendothelial system tumors, imaging, 16, 18, 18f
 Retinal degeneration, paraneoplastic, 431–32
 - antibodies, 426
- Retinoblastoma and p16-cdk4-pRb-cyclin D proteins, 245–46, 246f
 Ring lesions, imaging, 5f–6f, 29
 Ringertz's system of grading, 88–90, 88t
 Risperidone, 576, 576t
 Ritalin. *See* Methylphenidate
 Romberg's sign, 398
- Salk vaccine and brain tumors, 258–59
 Schwann cell and neuropathy, 400–401
 Schwannomas
 - cranial nerves III, IV, VI, X, 307–8
 - facial nerve, 306
 - imaging, 24–25
 - jugular foramen, 306–7, 307f
 - nasal cavity, 308
 - paranasal sinuses, 308
 - pathology, 302
 - skull base, 302–8, 303f–305f, 307f
 - trigeminal
 - diagnosis and treatment, 304–6, 305f
 - imaging, 16, 17f
 - vestibular
 - diagnosis and treatment, 302–4, 303f–304f
 - imaging, 15–16, 16f
- Schwannomin and meningiomas, 275
 Scintigraphy, 62–65, 62f, 64f–66f
 Sedation for diagnostic imaging, 4
 Seizures
 - behavioral changes and, 560
 - brain tumor symptoms, 76

- as cancer complication, 438–47
 - chemotherapy, 440–42
 - diagnosis, 444–45
 - etiology, 438–44, 439t
 - infection, 443
 - metabolic causes, 442–43
 - paraneoplastic syndromes, 440
 - primary and metastatic brain tumors, 438–40
 - radiotherapy, 440
 - stroke, 443–44
 - treatment, 445–47, 445f
 - intraoperative stimulation-induced, 81
 - metastatic brain tumors, 327, 438–40
 - mixed neuronal-glia tumor and, 98
 - pleomorphic xanthoastrocytomas and, 97
 - rehabilitation and, 472
 - surgical treatment, 101–3
 - treatment, 445–46
 - tuberous sclerosis and, 96
 - Selective serotonin reuptake inhibitors (SSRIs), 579–80, 579t
 - for anxiety, 581t, 582
 - Sensorimotor polyradiculoneuropathy, 402, 402t
 - Sensory neuropathy, 398–99, 398t
 - Sexual dysfunction and rehabilitation, 486
 - Shoulder pain and rehabilitation, 480
 - Sickness Impact Profile, 564
 - Single-photon emission computed tomography (SPECT), 62–65, 62f, 64f–66f
 - Single voxel (SV) technique, 55, 56f
 - Skin and wound care, 481–82, 482t
 - Skull base tumors, 300–319. *See also specific tumors*
 - anterior, 316–17, 316t
 - chondrosarcomas, 308–10, 310f
 - chordomas, 310–12, 311f
 - classification, 300, 301t–302t
 - location, 300, 301t
 - meningiomas, 300, 302
 - neurofibromatosis, 308
 - olfactory neuroblastomas, 314–16, 314t, 315f
 - paragangliomas, 312–14, 313f, 313t
 - pituitary adenomas, 302
 - schwannomas, 302–8, 303f–305f, 307f. *See also Schwannomas*
 - Skull metastasis and cancer pain, 501
 - Somatomedin, measurements of, 212–13, 212t
 - Somatosensory evoked potential (SSEP) in spinal surgery, 152
 - Somnolence syndrome, 384
 - Spasticity and rehabilitation, 480–81, 481t
 - Spectral karyotyping (SKY), 240
 - Spectral peak ratios, 55–57
 - Spectroscopy in vivo, 55–57, 56f
 - Speech deficits
 - psychotherapy and, 583
 - and rehabilitation, 473–74
 - Speech mapping, 79–84, 84f–86f
 - Sphenoid wing meningiomas, 278
 - Spinal cord compression
 - rehabilitation, 474–76, 475t
 - spinal metastases and, 344
 - Spinal tumors
 - intramedullary, 149, 150t
 - metastatic, 341–61
 - and cancer pain, 500–501
 - classification, 341, 342t–343t
 - imaging, 29–31, 37f–42f, 344–47, 344f–349f
 - incidence, 341–42
 - leptomeningeal, 376t–377t, 377
 - radiotherapy, 350–51, 350t–351t
 - vs. surgical treatment, 347–48, 350
 - surgical treatment
 - approaches, 354–57
 - decompression and stabilization, 355–57, 355f–357f, 356t, 358t–359t
 - extradural tumors, 353
 - indications, 351–52, 352t
 - intradural tumors, 352, 353f–354f
 - preoperative embolization, 354–55
 - strategies, 352–54, 352t, 353f–354f
 - symptoms and signs, 342, 344, 344t
 - treatment rationale, 347
 - primary, 149–57
 - chemotherapy, 154–55
 - classification, 149, 150t
 - clinical presentation, 150–52
 - epidemiology, 149–50, 150t
 - imaging, 22–25, 24f–25f, 28f–29f, 150, 151t
 - outcome, 155
 - radiotherapy, 154
 - surgical treatment, 152–54, 153f
- St. Anne-Mayo system of grading, 88–90, 88t
- Starling equation, 546
- Status epilepticus treatment, 445
- Stereotactic CT-coupled frames biopsy
 - brain tumors, primary, 77
 - germ cell tumors, 200
- Stereotactic-guided volumetric resections. *See* Radiosurgery
- Steroids
 - for altered mental status, 552–53
 - depression and, 577
 - myopathies induced by, 478–79
 - neurobehavioral changes, 559–60
 - rehabilitation and, 472
- Stroke. *See also* Cerebral hemorrhage; Cerebral infarction and seizures, 443
- Subacute motor neuronopathy, 432
- Subacute sensory neuronopathy, 430
- Subarachnoid hemorrhage
 - pituitary tumors and, 230
 - and seizures, 444
- Subdural hemorrhage
 - and coagulopathy, 456
 - and seizures, 444
- Subependymal giant cell astrocytomas
 - characteristics, 97
 - imaging, 10–11, 13f
 - surgical treatment, 102–3
- Subependymomas, fourth ventricle, 186–87, 186f
- Sufentanil, 516
- Suprasellar tumors, imaging, 11–15
- Supratentorial tumors. *See* Brain tumors
- Sustentacular cells in paragangliomas, 312

- SV40 virus and brain tumors, 258–59
- Sympathetically maintained pain, 497
- Synaptotagmin, 433
- Syncope as cancer complication
 - diagnosis, 449–50
 - etiology, 447–50, 448t
 - treatment, 450
- Syndrome of inappropriate antidiuretic hormone
 - after systemic treatment, 537
 - and neuropathy, 404
 - and opioid analgesics, 523
 - and seizures, 442–43
- Tamoxifen for meningiomas, 291
- Taxanes and iatrogenic neuropathy, 403–4, 403t
- Taxol
 - and iatrogenic neuropathy, 403–4, 403t
 - and seizures, 441
- Taxotere and iatrogenic neuropathy, 403t, 404
- Tegretol for seizures, 446
- Temporal lobe
 - brain tumor symptoms and, 76
 - language mapping, 82
- Teniposide and iatrogenic neuropathy, 404
- Tentorial meningiomas, 279
- Tep1 and tumor suppressor genes, 243
- Teratomas, 195–96. *See also* Germ cell tumors
 - cranial, 18
 - spinal, 25
- Testicular cancer and paraneoplastic neurologic disease, 423
- Thalamus and brain tumor symptoms, 76
- Thermal discrimination and neuropathy, 399
- Thiol compounds and neuroprotection, 407
- Thioridazine, 576, 576t
- Three-dimensional conformal photon radiation therapy, 116
- Throacotomy and cancer pain, 505
- Thrombic stroke and seizures, 443
- Thromboembolism, venous, 480
- Thyroid stimulating hormone (TSH)
 - after cancer treatment, 540
 - measurements of, 212–13, 212t
 - and pituitary tumors, 209–10. *See also* Pituitary tumors
 - treatment of, 225–26
- Thyrotropin. *See* Thyroid stimulating hormone (TSH)
- Tiagabine for seizures, 447
- Tic douloureux and epidermoid tumors, 18, 19f
- Tinea capitis radiation and brain tumors, 271
- Tobacco and brain tumors, 256
- Todd's paralysis, 472
- Tolerance and opioid analgesics, 522, 523
- Topamax for seizures, 447
- Topiramate for seizures, 447
- Topotecan, 388
- Torcular of Herophilus meningiomas, 279
- TP53* gene, 242
- Traction for cancer pain, 526
- Transport systems of axons, 401
- Transthyretin immunoreactivity, 132
- Tricyclic antidepressants
 - for cancer pain, 524
 - for depression, 579t, 580
 - for neuropathy, 406
- Trigeminal schwannomas
 - diagnosis and treatment, 304–6, 305f
 - imaging, 16, 17f
- Tuberculum sellae meningiomas, 278
- Tuberous sclerosis, 96–97
- Tubulin and Vinca, 404
- Tumor suppressor genes (TSGs)
 - etiology and epidemiology of brain tumors, 242–44
 - in meningiomas, 275–76
- Ultrasonography
 - brain tumor biopsy, 77
 - spinal, 152
- Urea for increased intracranial pressure, 552
- Vaccination and brain tumors, 258–59
- Valproic acid for seizures, 446
- Varicella virus and brain tumors, 259
- Vascular endothelial growth factor (VEGF) and meningiomas, 273–74
- Vasopressin, 213
- Vasovagal syncope, 449–50
- Venlafaxine for depression, 579t, 580
- Venous sinus thrombosis and seizures, 444
- Venous thromboembolism and rehabilitation, 480
- Verocay bodies, 302
- Vestibular schwannomas
 - diagnosis and treatment, 302–4, 303f–304f
 - imaging, 15–16, 16f
 - rehabilitation and, 473
- VHL* gene, 244
- Vinca and iatrogenic neuropathy, 403–4, 403t
- Vincristine and iatrogenic neuropathy, 403–4, 403t
- Vinyl chloride and brain tumors, 258
- Viruses and brain tumors, 258–59
- Vitamins and brain tumor etiology, 255
- Vocational rehabilitation, 566–67
- Volume of interest (VOI) in in vivo spectroscopy, 55, 56f
- von Hippel-Lindau syndrome
 - hemangioblastomas and, 20, 23, 149
 - tumor suppressor genes and, 244
- von Recklinghausen's disease and pleomorphic xanthoastrocytomas, 97
- “Winking owl” sign, 344, 345f–347f
- World Health Organization (WHO) system of grading, 88–90, 88t
- Xanthoastrocytomas, pleomorphic, 97